DT-5461 是一种 IL-1 和 TNF-α 拮抗剂,可竞争性结合巨噬细胞受体上的脂质 A 结合位点,阻断 LPS (MS-X54539) 启动的信号通路,抑制 LPS 诱导的细胞因子释放,预防 LPS 诱导的小鼠血清细胞因子生成,并对 LPS 诱导的致死性内毒素血症具有保护作用,可用于致死性内毒素血症、髓样管状乳腺癌、低分化结肠腺癌、鳞状细胞肺癌及胶样胃腺癌的相关研究。
产品编号: MS-K41539 CAS No.: 123598-19-6 分子式: C73H133N4O22P 分子量: 1449.82
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

DT-5461 是一种 IL-1 和 TNF-α 拮抗剂,可竞争性结合巨噬细胞受体上的脂质 A 结合位点,阻断 LPS (MS-X54539) 启动的信号通路,抑制 LPS 诱导的细胞因子释放,预防 LPS 诱导的小鼠血清细胞因子生成,并对 LPS 诱导的致死性内毒素血症具有保护作用,可用于致死性内毒素血症、髓样管状乳腺癌、低分化结肠腺癌、鳞状细胞肺癌及胶样胃腺癌的相关研究。

生物实验数据

生物活性 DT-5461 is an IL-1 and TNF-α antagonist that competitively binds to the lipid A-binding site on macrophage receptors, blocks the signaling pathway initiated by LPS (MS-X54539), inhibits LPS-induced cytokine release, prevents LPS-induced serum cytokine production in mice, and exerts a protective effect against LPS-induced lethal endotoxemia, making it suitable for research on lethal endotoxemia, medullary tubular breast cancer, poorly differentiated colon adenocarcinoma, squamous cell lung cancer, and colloid gastric adenocarcinoma.
IC50 & Target

IL-1

 

体外研究
(In Vitro)

DT-5461 (0.1-10 μg/mL;2 小时预处理) 可作为人外周血单核细胞中的 LPS 拮抗剂,以浓度依赖方式显著抑制 E. coli LPS 诱导的 IL-1 和 TNF-α 分泌,在 10 μg/mL 时观察到最大抑制效果。
DT-5461 (10 μg/mL;4 小时) 可刺激经 IFN-γ 处理的裸鼠腹腔巨噬细胞产生 TNF;当与 PC-6、QG56 或 MX-1 人肿瘤细胞共培养时,TNF 的产生量可增加 2 至 4 倍,其中 MX-1 细胞的增强作用最强。

体内研究
(In Vivo)

DT-5461 (每只小鼠 1-100 μg;腹腔注射;单次给药) 可剂量依赖性地预防脂多糖 (LPS) 诱导的 D-半乳糖胺致敏 C57BL/6 小鼠致死性内毒素血症,在每只小鼠 100 μg 的剂量下可实现 100%的存活率,并能抑制 LPS 介导的血清 IL-1 和 TNF-α 的产生。
DT-5461 (静脉注射;4-6 次给药) 在未处理的雄性 Sprague-Dawley 大鼠中,单次静脉推注的 LD50 大于 68000 ng/kg,静脉滴注的 LD50 大于 20000 ng/kg,在测试剂量下不同给药途径的致死率无差异。
DT-5461 (静脉注射;4-6 次给药) 在 2/3 肝切除的雄性 Sprague-Dawley 大鼠中经静脉推注给药的 LD50 大于 400 ng/kg,与 C506 和 LPS 相比,其致死性增强但效力更低。
DT-5461 (35 mg/kg;静脉注射;单次给药) 可在未处理的雄性 Sprague-Dawley 大鼠中诱发持续性脾肿大、血细胞计数和血清 IgG 的一过性升高,以及脾脏 B 细胞和 T 细胞群体的变化,并伴有特征性组织病理学改变。
DT-5461 (1.0-2.5 mg/kg;静脉滴注;单次给药) 不会在经 0.4 M lactic acid 预处理的雄性 Sprague-Dawley 大鼠中诱发弥散性血管内凝血 (DIC) 相关的临床病理改变。
DT-5461 (0.64-10 mg/kg;静脉注射;每日 1 次;连续 14 天) 可在雄性 Sprague-Dawley 大鼠中引发:剂量≥0.64 mg/kg 时出现脾肿大,剂量≥4 mg/kg 时出现血小板计数降低和肝细胞坏死,剂量为 10 mg/kg 时出现血清丙氨酸氨基转移酶升高。
DT-5461 (4-25 mg/kg;静脉注射;每日一次;连续 14 天) 对雄性松鼠猴的作用表现为:4 mg/kg 剂量下无变化,10 mg/kg 剂量下出现轻微肝细胞坏死和网状内皮系统激活,25 mg/kg 剂量下则出现血清丙氨酸氨基转移酶升高、广泛肝细胞坏死及网状内皮系统激活。
DT-5461 (每只小鼠 200 μg;静脉注射;每 5 天 1 次,共 3 次) 对 BALB/c 小鼠体内的 Meth A 纤维肉瘤表现出显著的抗肿瘤活性,T/C 值达 29%。
DT-5461 (每只小鼠 200 μg;静脉注射;每 5 天 1 次,共 3 次) 在 BALB/c-nu/nu 小鼠中对 Meth A 纤维肉瘤表现出显著的抗肿瘤活性,T/C 值达 35%。
DT-5461 (每只小鼠 200-800 μg;静脉注射;每 3 天 1 次,共 9 次) 在 BALB/c-nu/nu 小鼠中对 PC-6 燕麦细胞肺癌表现出剂量依赖性、具有统计学意义的抗肿瘤活性,200 μg/小鼠剂量下的 T/C 值为 21%,800 μg/小鼠剂量下为 8%,并能诱导与抗肿瘤疗效相关的瘤内 TNF 活性。
DT-5461 (每只小鼠 200-800 μg;静脉注射;每 3 天 1 次,共 9 次) 在 BALB/c-nu/nu 小鼠中对 MX-1 髓样管状乳腺癌表现出剂量依赖性、具有统计学意义的抗肿瘤活性,200 μg/小鼠剂量下的 T/C 值为 30%,800 μg/小鼠剂量下为 14%,并能诱导与抗肿瘤疗效相关的高水平瘤内 TNF 活性。
DT-5461 (每只小鼠 200-800 μg;静脉注射;每 3 天 1 次,共 9 次) 在 BALB/c-nu/nu 小鼠中对低分化结肠腺癌 Co-4 表现出具有统计学意义的抗肿瘤活性,200 μg/小鼠剂量下的 T/C 值为 27%,800 μg/小鼠剂量下的 T/C 值为 29%,并能诱导与抗肿瘤疗效相关的高水平瘤内 TNF 活性。
DT-5461 (每只小鼠 200-800 μg;静脉注射;每 3 天 1 次,共 9 次) 在 BALB/c-nu/nu 小鼠中对 QG56 肺鳞状细胞癌表现出剂量依赖性的、具有统计学意义的抗肿瘤活性,200 μg/小鼠剂量下的 T/C 值为 54%,800 μg/小鼠剂量下为 27%,并能诱导与抗肿瘤疗效相关的瘤内 TNF 活性。
DT-5461 (每只小鼠 200-800 μg;静脉注射;每 3 天 1 次,共 9 次) 对 BALB/c-nu/nu 小鼠体内的 SC-6 低分化胃腺癌表现出剂量依赖性抗肿瘤活性,在 800 μg/mouse 剂量下 T/C 值达 32%,具有统计学显著性,同时可诱导与抗肿瘤疗效相关的瘤内 TNF 活性。
DT-5461 (每只小鼠 200-800 μg;静脉注射;每 3 天 1 次,共 9 次) 对 BALB/c-nu/nu 小鼠体内的 St-15 胶状胃腺癌表现出微弱的抗肿瘤活性,200 μg/mouse 剂量下的 T/C 值为 72%,800 μg/mouse 剂量下的 T/C 值为 57%,且可诱导低水平的瘤内 TNF 活性。

Animal Model: C57BL/6 (female, 7-10 weeks old, specific-pathogen-free, sensitized with E. coli 0127:B8 LPS and D-galactosamine for lethal endotoxemia model)
Dosage: 1 μg per mouse; 10 μg per mouse; 100 μg per mouse
Administration: i.p.; single dose
Result: Inhibited LPS-mediated increases in endogenous serum IL-1 and TNF-α in a dose-dependent manner.
Reduced serum IL-1 and TNF-α levels significantly relative to LPS-only controls at 1 μg per mouse.
Achieved greater reductions in serum IL-1 and TNF-α levels at 10 μg per mouse.
Suppressed serum IL-1 and TNF-α levels most strongly at 100 μg per mouse (P < 0.001 vs.
LPS-only group).
Resulted in 37.5% (3/8) survival rate through day 6 at 1 μg per mouse.
Resulted in 75% (6/8) survival rate through day 6 at 10 μg per mouse.
Resulted in 100% (8/8) survival rate through day 6 at 100 μg per mouse.
Had a 50% protection dose of 2.1 μg per mouse and a 100% protection dose of 25 μg per mouse.
Animal Model: Sprague-Dawley (male, 8-9 weeks old, 220-260 g)
Dosage: 35 mg/kg
Administration: i.v.; single bolus injection
Result: Induced splenomegaly from day 1, with no full recovery to control levels by day 28.
Caused a marked increase in white blood cell, lymphocyte, and neutrophil counts on days 3-6, returning to baseline by day 28.
Induced serum IgG levels to peak between days 2-6, mirroring white blood cell fluctuations.
Caused splenic nucleated cells to increase from day 3.
Induced B-cells to significantly increase from day 3, and T-cells to increase from day 14.
Caused enlargement of B-cell area lymphatic follicles with large phagocytic cell infiltration and decreased T-cell area lymphocytes from 6 h to day 3.
Triggered lympho-reticular cell proliferation in the red pulp zone from days 1-28.
Induced megakaryopoiesis on days 2-6, and enhanced erythropoiesis on days 4-6.
Animal Model: Sprague-Dawley (male, 8-9 weeks old, 220-260 g, lactic acid-pretreated)
Dosage: 1.0 mg/kg; 2.5 mg/kg
Administration: i.v.; drip infusion; single dose
Result: Caused no changes in platelet counts, activated partial thromboplastin time, fibrin-fibrinogen degradation products, serum alanine aminotransferase, or urea nitrogen at both 1.0 mg/kg and 2.5 mg/kg.
Showed no hepatocellular necrosis or glomerular fibrin thrombus formation at both doses, unlike C506 and LPS.
Animal Model: Sprague-Dawley (male, 8-9 weeks old, 220-260 g)
Dosage: 0.64 mg/kg; 1.6 mg/kg; 4 mg/kg; 10 mg/kg
Administration: i.v.; bolus injection; daily; 14 days
Result: Induced splenomegaly at all doses (0.64 mg/kg or more).
Caused decreased platelet counts and single hepatocellular necrosis at 4 mg/kg or more.
Induced increased serum alanine aminotransferase activity at 10 mg/kg.
Animal Model: Squirrel monkey (male, over 4 years old, 0.7-1 kg)
Dosage: 4 mg/kg; 10 mg/kg; 25 mg/kg
Administration: i.v.; bolus injection; daily; 14 days
Result: Caused no changes at 4 mg/kg.
Induced slight hepatocellular necrosis and moderate activation of the hepatic and splenic reticuloendothelial system at 10 mg/kg.
Caused increased serum alanine aminotransferase activity, extensive hepatocellular necrosis, and extensive activation of the hepatic and splenic reticuloendothelial system at 25 mg/kg.
Showed no effects on organ weights at any dose.
Animal Model: BALB/c (male, 6-week-old, intradermal inoculation of Meth A fibrosarcoma cells)
Dosage: 200 μg/mouse
Administration: i.v.; three times at 5-day intervals
Result: Produced a statistically significant tumor growth inhibitory effect with a T/C value of 29% relative to control mice.
Animal Model: BALB/c-nu/nu (nude, male, 6-week-old, intradermal inoculation of Meth A fibrosarcoma cells)
Dosage: 200 μg/mouse
Administration: i.v.; three times at 5-day intervals
Result: Produced a statistically significant tumor growth inhibitory effect with a T/C value of 35% relative to control mice.
Animal Model: BALB/c-nu/nu (nude, male, 6-week-old, subcutaneous transplantation of PC-6 tumor pieces)
Dosage: 200 μg/mouse; 800 μg/mouse
Administration: i.v.; 9 times at 3-day intervals
Result: Produced a mean tumor weight of 0.65 g, a statistically significant T/C value of 21% relative to control mice at 200 μg/mouse.
Produced a mean tumor weight of 0.24 g, a statistically significant T/C value of 8% relative to control mice at 800 μg/mouse.
Induced intratumoral TNF activity with a single i.v.
dose of 200 μg/mouse.
Induced higher intratumoral TNF activity and serum TNF activity with a single i.v.
dose of 800 μg/mouse.
Animal Model: BALB/c-nu/nu (nude, male, 6-week-old, subcutaneous transplantation of MX-1 tumor pieces)
Dosage: 200 μg/mouse; 800 μg/mouse
Administration: i.v.; 9 times at 3-day intervals
Result: Produced a mean tumor weight of 1.98 g, a statistically significant T/C value of 30% relative to control mice at 200 μg/mouse.
Produced a mean tumor weight of 0.90 g, a statistically significant T/C value of 14% relative to control mice at 800 μg/mouse.
Induced intratumoral TNF activity with a single i.v.
dose of 200 μg/mouse.
Induced higher intratumoral TNF activity and serum TNF activity with a single i.v.
dose of 800 μg/mouse.
Augmented DT-5461-stimulated macrophage TNF production 4-fold in vitro by MX-1 tumor cells.
Animal Model: BALB/c-nu/nu (nude, male, 6-week-old, subcutaneous transplantation of Co-4 tumor pieces)
Dosage: 200 μg/mouse; 800 μg/mouse
Administration: i.v.; 9 times at 3-day intervals
Result: Produced a mean tumor weight of 0.49 g, a statistically significant T/C value of 27% relative to control mice at 200 μg/mouse.
Produced a mean tumor weight of 0.51 g, a statistically significant T/C value of 29% relative to control mice at 800 μg/mouse.
Induced intratumoral TNF activity with a single i.v.
dose of 200 μg/mouse.
Induced higher intratumoral TNF activity and serum TNF activity with a single i.v.
dose of 800 μg/mouse.
Animal Model: BALB/c-nu/nu (nude, male, 6-week-old, subcutaneous transplantation of QG56 tumor pieces)
Dosage: 200 μg/mouse; 800 μg/mouse
Administration: i.v.; 9 times at 3-day intervals
Result: Produced a mean tumor weight of 1.97 g, a statistically significant T/C value of 54% relative to control mice at 200 μg/mouse.
Produced a mean tumor weight of 0.98 g, a statistically significant T/C value of 27% relative to control mice at 800 μg/mouse.
Induced intratumoral TNF activity with a single i.v.
dose of 200 μg/mouse.
Induced higher intratumoral TNF activity and serum TNF activity with a single i.v.
dose of 800 μg/mouse.
Augmented DT-5461-stimulated macrophage TNF production 2-fold in vitro by QG56 tumor cells.
Animal Model: BALB/c-nu/nu (nude, male, 6-week-old, subcutaneous transplantation of SC-6 tumor pieces)
Dosage: 200 μg/mouse; 800 μg/mouse
Administration: i.v.; 9 times at 3-day intervals
Result: Produced a mean tumor weight of 1.37 g, a T/C value of 44% relative to control mice at 200 μg/mouse.
Produced a mean tumor weight of 1.01 g, a statistically significant T/C value of 32% relative to control mice at 800 μg/mouse.
Induced intratumoral TNF activity with a single i.v.
dose of 200 μg/mouse.
Induced higher intratumoral TNF activity and serum TNF activity with a single i.v.
dose of 800 μg/mouse.
Animal Model: BALB/c-nu/nu (nude, male, 6-week-old, subcutaneous transplantation of St-15 tumor pieces)
Dosage: 200 μg/mouse; 800 μg/mouse
Administration: i.v.; 9 times at 3-day intervals
Result: Produced a mean tumor weight of 1.00 g, a T/C value of 72% relative to control mice at 200 μg/mouse.
Produced a mean tumor weight of 0.79 g, a T/C value of 57% relative to control mice at 800 μg/mouse.
Induced low intratumoral TNF activity with a single i.v.
dose of 200 μg/mouse.
Induced higher intratumoral TNF activity and serum TNF activity with a single i.v.
dose of 800 μg/mouse.

化学信息

分子量 1449.82
分子式 C73H133N4O22P
CAS No. 123598-19-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础